Nichi-Iko Pharmaceutical and Sagent Pharmaceuticals, a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals ("Xellia").
Bausch Health announced that the company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals for a cash purchase price of approximately $195m and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with the company.
Science and technology firm Danaher has agreed to acquire the biopharma business of GE Life Sciences (GE Biopharma) for a cash purchase price of about $21.4bn.
The US affiliate of specialty pharmaceutical company Indivior has introduced an authorized generic version of Suboxone (buprenorphine and naloxone) sublingual film in the US.
UK-based Clinigen Group has agreed to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Novartis in an all-cash deal worth up to $210m.
ValGenesis has announced that one of the world's largest, top rated life science companies has chosen to implement its 100% paperless Validation Lifecycle Management System (VLMS) across all its global sites to manage the corporate validation lifecycle process.
Mayne Pharma Group, a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, has launched LEXETTE (halobetasol propionate) Foam 0.05% in the US.
Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), has announced the acquisition of Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma.
apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy, announced that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma.
NextPharma, a European pharmaceutical contract development and manufacturing organization (CDMO), has agreed to acquire Santen’s Tampere manufacturing facility and associated operations.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.